Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia

2014220 citationsJournal Article

Authors

Tamera J. Corte · The University of Sydney

Gregory J. Keir · Princess Alexandra Hospital

Konstantinos Dimopoulos · Pulmonary Hypertension Association

Luke Howard · Hammersmith Hospital

Paul A. Corris · Freeman Hospital

Lisa Parfitt · Pulmonary Hypertension Association

Claire Foley

Abstract

This study shows no difference in invasive pulmonary hemodynamics, functional capacity, or symptoms between the bosentan and placebo groups over 16 weeks. Our data do not support the use of the dual endothelin-1 receptor antagonist, bosentan, in patients with PH and fibrotic IIP. Clinical trial registered with www.clinicaltrials.gov (NCT 00637065).

Topics & Keywords

Pulmonary Hypertension Research and Treatments Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Medical Imaging and Pathology Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Respiratory and Critical Care Medicine

Volume 190, Issue 2, pp. 208-217

DOI: 10.1164/rccm.201403-0446oc

Field-Weighted Citation Impact: 15.93